Medacta Group Ltd

MOVE

Equity

ISIN CH0468525222 / Valor 46852522

SIX Swiss Exchange (2025-11-17)

CHF 150.80-0.79%

Medacta Group Ltd
UMushroom community rating:

3.50 2 votes No rating yet

NegativeNeutralPositive

About company

Medacta Group Ltd is a Swiss-based company specializing in the development, manufacture, and sale of orthopaedic products and surgical techniques. Founded in 1999 by Dr. Alberto Siccardi, the company has focused on innovation in the field of orthopaedics, including minimally invasive surgery (MIS) and personalized medicine solutions. Medacta has expanded its product range to include knee, hip, and spine implants, as well as computer-assisted surgery systems. The company also emphasizes medical education through its M.O.R.E. (Medacta Orthopaedic Research and Education) Institute, which supports the dissemination of its surgical techniques. In 2019, Medacta celebrated its 20th anniversary by becoming a publicly listed company on the SIX Swiss Exchange. Over the years, Medacta has grown internationally, establishing subsidiaries and expanding its market presence across Europe, the United States, Asia, and Australia.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Medacta achieved a revenue of €590.6 million in 2024, representing a 16.2% increase in constant currency and a 15.6% growth in Euro terms.

EBITDA Improvement

Adjusted EBITDA rose by 19.4% to €160.2 million, resulting in a margin of 27.1%, compared to €134.2 million and a 26.3% margin in 2023.

Profit Increase

The profit for the year stood at €72.9 million, accounting for 12.3% of revenue, up from €47.4 million in the previous year.

Cash Flow

Adjusted Free Cash Flow significantly increased to €25.9 million in 2024, up from €6.7 million in 2023.

Dividend Distribution

The Board of Directors proposed a distribution of CHF 0.69 per share for 2024, marking a 25% year-over-year increase from CHF 0.55 in 2023.

Future Outlook

For FY 2025, Medacta targets a revenue growth of 13% to 15% in constant currency and aims to maintain an adjusted EBITDA margin of around 27%, factoring in recent acquisitions and market conditions.

Summarized from source with an LLMView Source

Key figures

33.5%1Y

45.6%3Y

77.8%5Y

Performance

29.7%1Y

28.3%3Y

32.0%5Y

Volatility